The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Source of stem cell
Allogeneic
Autologous
Origin of stem cell
- Adult
- Embryonic
- Type of stem cell
- Hematopoietic
- Mesenchymal
- Progenitor
- Others
Lineage of stem cell
Adipose Tissue
Bone Marrow
Cord Blood
Others
Route of Administration
Intraarticular
Intracoronary
Intramuscular
Intramyocardial
Intrathecal
Intravenous
Surgical Implantations
Others
Therapeutic Area
Autoimmune / Inflammatory Disorder
Cardiovascular Disorders
Metabolic Disorder
Musculoskeletal Disorders
Oncological Disorders
Neurological Disorders
Ophthalmic Disorders
Others
End Users
Ambulatory Surgery Centers
Hospitals
Specialty Clinics
Key Geographies
North America
Europe
- Asia-Pacific and Rest of the World
The report includes detailed transcripts of discussions held with the following experts:
- William L Rust (Founder and Chief Executive Officer, Seraxis)
- Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
- Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
- Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
- Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)
- Gilles Devillers (President, Bio Elpida)
- Fiona Bellot (Business Development Manager, Roslin Cell Therapies)
- David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
- Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)
To request sample pages, please visit this – https://www.rootsanalysis.com/reports/296/request-sample.html
Key Questions Answered
- Who are the leading developers of stem cell therapies?
- Which types of clinical conditions can be treated using stem cell therapies?
- Which cell lineages and types of stem cells are commonly used for therapy development?
- What kind of key commercialization strategies are being used by stem cell therapy developers?
- Who are the key contract service providers engaged in this domain?
- How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
- Stem Cell Therapy Contract Manufacturing Market, 2019-2030
- Antibody Drug Conjugates Market (5th Edition), 2019-2030
- Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
- Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
